Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or nonpregnant female, ages 18 to 70 years inclusive, at Screening Visit.~2. Biopsy-confirmed CD (intestinal histology showing villous atrophy).~3. Positive for human leukocyte antigen (HLA)-DQ2 or HLA-DQ2/DQ8 - results will be obtained at Screening if unknown or results are not available.~4. Self-reported to be on a GFD for at least 6 months prior to Screening and agree to continue GFD throughout study, with the exception of the oral gluten challenge.~Normal or negative celiac serology, at screening, defined as:~1. Measurable total serum immunoglobulin A (IgA) AND~2. Negative or weak positive tissue transglutaminase (tTG) IgA titer OR~3. If IgA deficient, defined by a serum IgA level of \< 3 mg/dL, negative or weak positive DGP- IgG titer.~   6. Vh:Cd ≥ 1.5 on screening biopsy.~   Key Exclusion Criteria:~  1. Positive for only HLA-DQ8.~  2. History of clinically confirmed immunoglobulin E (IgE)-mediated reaction and/or anaphylaxis to wheat (i.e., wheat allergy), barley or rye.~  3. Uncontrolled CD and/or active signs/symptoms of CD, in the opinion of the investigator.~  4. Untreated or active gastrointestinal disease such as peptic ulcer disease, esophagitis (Los Angeles Classification ≥ Grade C), irritable bowel syndrome, inflammatory bowel disease, or microscopic colitis.~  5. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior Dose 1, any dose of corticosteroids within 30 days of Day 1, or high dose inhaled corticosteroids \[\> 960 µg/day of beclomethasone dipropionate or equivalent\]) or other immunosuppressive agents.~  6. Presence or history of celiac-associated thyroid disease or Type 1 diabetes, regardless of current treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TIMP-GLIA (Type: EXPERIMENTAL): 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline administered intravenously on days 1 and 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).